中文
About Us
About Us
Green Valley is an innovative Chinese pharmaceutical company that pioneers carbohydrate drugs development and manufacturing in the world.
About Green Valley
Our Business
Mission & Vision
Our Culture
Code of Business Ethics
GV-971
GV-971
Here you can get access to more information of GV-971.
Products
News Reports
Research Highlights
Milestones
Scientific Research Information
Scientific Research Information
Originality is the soul of our innovation in scientific research. We are devoted to developing drugs and healthcare solutions that patients are in the greatest need of.
Life Sciences Innovation
Research Parteners
News
News
Here you can get access to the latest news reports of Green Valley.
Press Releases
News Reports
Social Responsibility
Careers
Careers
Apart from the competitive compensation & benefits programs, we have developed a detailed benefits and perks scheme. We respect, appreciate and reward the contributions of every employee for their hard work and dedication.
Job Search
Salary and Benefits
Contact Us
Contact Us
Media Contacts
CN
News Reports

News Reports
Products
News Reports
Research Highlights
Milestones
Products
News Reports
Research Highlights
Milestones
10-25
2018
Xinhua Net | China's new drug might give Alzheimer patients hope: lead researcher
BARCELONA, Spain, Oct. 25 (Xinhua) -- GV-971, a multi-targeting oligosaccharide drug developed by a Chinese research group, could give Alzheimer patients hope, lead researcher Geng Meiyu told Xinhua on Thursday.
10-25
2018
CCTV-NEWS | GV-971, a novel AD drug treatment developed by Chinese research team, grabs much of attention at CTAD
10-26
2018
China Daily | China's new drug might give Alzheimer patients hope: lead researcher
10-25
2018
YAHOO! | Novel Drug Treatment Shows Improved Cognition in a Phase 3 Clinical Trial in Persons with Mild-to-Moderate Alzheimer's Disease in China
​BARCELONA, Spain, Oct. 25, 2018 /PRNewswire/ -- Green Valley Pharmaceutical Co., Ltd. (Headquarter: Shanghai) announced promising findings from a Phase 3 clinical trial of GV-971, a multi targeting carbohydrate-based drug, with 818 patients across 34 sites in China for treatment of patients with mild-to-moderate Alzheimer's disease at the 11thClinical Trials on Alzheimer's Disease Conference (CTAD) in Barcelona, Spain.